Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation
Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF
Record ID 32010000256
English
Authors' recommendations:
Study found rituximab and abatacept to be more effective compared with supportive care (including ongoing disease-modifying antirheumatic drugs) in rheumatoid arthritis after failure of a TNF inhibitor. Use of an alternative TNF inhibitor in this patient population may provide some benefit according to evidence from observational studies, but there remain uncertainties with regard to the magnitude of the benefit and its cost-effectiveness.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2055
Year Published:
2011
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Adalimumab
- Etanercept
- Infliximab
- Rituximab
- Abatacept
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.